<DOC>
	<DOC>NCT01255358</DOC>
	<brief_summary>Multi-centre, single arm, open label, 6 months, phase II study to evaluate the effect of Ery-Dex in improving Central Nervous System (CNS) symptoms in patients with Ataxia Teleangiectasia (AT). The study consists of a screening period (max duration of 30 days) and a treatment period (duration 6 months).</brief_summary>
	<brief_title>Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients</brief_title>
	<detailed_description>The study has the aim to evaluate the improvement in CNS symptoms measured by International Co-operative Ataxia Rating Scale (ICARS) in patients with AT, during a period of treatment with Ery-Dex (dexamethasone sodium phosphate ex vivo encapsulated into human autologous erythrocytes).</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>neurological signs of AT patients in autonomous gait or helped by a support proven molecular diagnosis of AT Males and females aged &gt; 3 years Body weight &gt;15 kg Plasma levels of Lymphocytes CD4+/mm3 &gt; 500 (for patients aged 36 years) or &gt; 200 (older than 6 years) Current or previous neoplastic disease History of severe impairment of the immunological system Chronic conditions representing a contraindication to the use of steroid drugs Non compliance with the study request Any previous steroid assumption within 30 days before starting EryDex</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Ataxia Teleangiectasia</keyword>
	<keyword>AT</keyword>
	<keyword>Ery-Dex</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Dexamethasone sodium phosphate</keyword>
</DOC>